Joy Yan
Chief Tech/Sci/R&D Officer presso KEYMED BIOSCIENCES INC.
Patrimonio netto: - $ in data 31/03/2024
Posizioni attive di Joy Yan
Società | Posizione | Inizio | Fine |
---|---|---|---|
MOLECULIN BIOTECH, INC. | Director/Board Member | 01/03/2022 | - |
KEYMED BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 01/01/2022 | - |
Storia della carriera di Joy Yan
Precedenti posizioni note di Joy Yan
Società | Posizione | Inizio | Fine |
---|---|---|---|
CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 20/12/2021 | 31/05/2022 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | 01/10/2020 | - |
BAYER AG | Corporate Officer/Principal | - | - |
AMBRX INC | Chief Tech/Sci/R&D Officer | 01/10/2020 | - |
Formazione di Joy Yan
The Johns Hopkins University | Doctorate Degree |
China Medical University | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Isole Cayman | 3 |
Germania | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 2 |
Director/Board Member | 2 |
Settori
Health Technology | 7 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
BAYER AG | Health Technology |
MOLECULIN BIOTECH, INC. | Health Technology |
KEYMED BIOSCIENCES INC. | Health Technology |
Aziende private | 3 |
---|---|
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
- Borsa valori
- Insiders
- Joy Yan
- Esperienza